Your browser doesn't support javascript.
loading
MacroH2A histone variants modulate enhancer activity to repress oncogenic programs and cellular reprogramming.
Mohammed Ismail, Wazim; Mazzone, Amelia; Ghiraldini, Flavia G; Kaur, Jagneet; Bains, Manvir; Munankarmy, Amik; Bagwell, Monique S; Safgren, Stephanie L; Moore-Weiss, John; Buciuc, Marina; Shimp, Lynzie; Leach, Kelsey A; Duarte, Luis F; Nagi, Chandandeep S; Carcamo, Saul; Chung, Chi-Yeh; Hasson, Dan; Dadgar, Neda; Zhong, Jian; Lee, Jeong-Heon; Couch, Fergus J; Revzin, Alexander; Ordog, Tamas; Bernstein, Emily; Gaspar-Maia, Alexandre.
Affiliation
  • Mohammed Ismail W; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Mazzone A; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Ghiraldini FG; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Kaur J; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Bains M; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Munankarmy A; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Bagwell MS; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Safgren SL; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Moore-Weiss J; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Buciuc M; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Shimp L; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Leach KA; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Duarte LF; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Nagi CS; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Carcamo S; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Chung CY; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Hasson D; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Dadgar N; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Zhong J; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Lee JH; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Couch FJ; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Revzin A; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Ordog T; Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Bernstein E; Center for Individualized Medicine, Epigenomics program, Mayo Clinic, Rochester, MN, USA.
  • Gaspar-Maia A; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Commun Biol ; 6(1): 215, 2023 02 23.
Article in En | MEDLINE | ID: mdl-36823213
Considerable efforts have been made to characterize active enhancer elements, which can be annotated by accessible chromatin and H3 lysine 27 acetylation (H3K27ac). However, apart from poised enhancers that are observed in early stages of development and putative silencers, the functional significance of cis-regulatory elements lacking H3K27ac is poorly understood. Here we show that macroH2A histone variants mark a subset of enhancers in normal and cancer cells, which we coined 'macro-Bound Enhancers', that modulate enhancer activity. We find macroH2A variants localized at enhancer elements that are devoid of H3K27ac in a cell type-specific manner, indicating a role for macroH2A at inactive enhancers to maintain cell identity. In following, reactivation of macro-bound enhancers is associated with oncogenic programs in breast cancer and their repressive role is correlated with the activity of macroH2A2 as a negative regulator of BRD4 chromatin occupancy. Finally, through single cell epigenomic profiling of normal mammary stem cells derived from mice, we show that macroH2A deficiency facilitates increased activity of transcription factors associated with stem cell activity.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription Factors / Nuclear Proteins Limits: Animals Language: En Journal: Commun Biol Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription Factors / Nuclear Proteins Limits: Animals Language: En Journal: Commun Biol Year: 2023 Type: Article Affiliation country: United States